Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | LIPE | Q05469 | 7/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24344109 | 1.00 | DUT (0.34) | DUTLIPEDGAT1LPLLIPG | |
| SCHEMBL30326245 | 0.83 | DGAT1 (0.31) | DUTDGAT1HTT | |
| SCHEMBL26601952 | 0.83 | MAPT (0.34) | DUTDGAT1NPSR1 | |
| SCHEMBL26636093 | 0.83 | MAPT (0.34) | DUTDGAT1LMNAHTTSLC2A1 | |
| SCHEMBL13043663 | 0.81 | LPL (0.40) | LIPEDGAT1LPLLIPGTDP1 | |
| SCHEMBL18174184 | 0.81 | LPL (0.40) | LPLLIPGLMNATDP1 | |
| SCHEMBL29534512 | 0.80 | LPL (0.37) | LIPELPLLIPGLMNAHTT | |
| SCHEMBL262387 | 0.80 | LPL (0.37) | LIPELPLLIPGLMNAHTT | |
| SCHEMBL18667453 | 0.80 | CXCR2 (0.37) | DUTLIPELPLLIPGCXCR2 | |
| SCHEMBL29079901 | 0.79 | LPL (0.36) | LIPEDGAT1LPLLIPGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225742-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |